This year the company was dealing with generic competition for Zegerid and a manufacturing recall for Glumetza (500 mg tablets only)and they went through a staff reduction to reduce their costs to the new expectations.
Now we expect an announcement that manufacturing on those tablets have resumed. That should happen within a month. Cycloset was launched in November. We will start to get some indication on expected sales there. Rhucin is in the FDA approval cycle and should launch in the 2nd half of 2011, if all goes well. They will also submit an NDA for Budesonide in the 2nd half of 2011, as the European trials have gone well.
The stock had rightfully been depressed this year due to the problems that were encountered. There is a lot of good news out there this year with multiple drugs already approved with other drugs moving quickly toward approval. I honestly believe we will see $6 a share this year as more of this development comes to fruition. That would only be a $360M market cap, so I believe that is a reasonable number, unless they suffer more setbacks. I just believe at this point, the bad news is behind them.